US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion ... With a portfolio of iconic brands, such as Allegra, Doliprane ...

Sanofi SAN-0.42%decrease; red down pointing triangle moved ahead with a plan to sell a controlling stake in its consumer-healthcare unit ... business that is home to brands such as Allegra ...

Sanofi and CD&R partner to ... to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand portfolio and its highly skilled and ...

Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra and Dulcolax. Sanofi SA SNY and private equity Clayton Dubilier ...

Opella employs 11,000 people globally and sells popular French pain medicine Doliprane, as well as brands ... Sanofi, which said a year ago it was reviewing separation scenarios for its consumer ...

Sanofi and CD&R enter exclusive negotiations ... innovation and growth to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand ...